This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet (London, England), 402(10403), 705-719
Citation
Knop, Filip K; Aroda, Vanita R; do Vale, Ruben D; Holst-Hansen, Thomas; Laursen, Peter N; Rosenstock, Julio; Rubino, Domenica M; Garvey, W Timothy. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet (London, England), 402(10403), 705-719. https://doi.org/10.1016/S0140-6736(23)01185-6